Xinhua Medical: To terminate the acquisition of 36.1913% equity of Wuhan Zhongzhi Biotechnology.

Xinhua Medical announced that the company originally planned to acquire 36.1913% equity of Zhongzhi Biosciences, passing the relevant resolution on December 30, 2024. As of the announcement date, the delivery deadline stipulated in the Share Transfer Agreement has passed, and it was decided to terminate the agreement after negotiation. The company has signed a Supplementary Agreement to the Share Transfer Agreement with some of the trading parties, and has sent a Notice of Termination of Share Transfer Agreement to other parties. Since the payment prerequisite was not met, the company did not make the payment, and the termination of the acquisition will not have a negative impact on the current operating performance and financial condition.